INOVIO Submits EMA Application for VOCERYQ in RRP
Pennsylvania, USA, November 18, 2026 INOVIO has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Pennsylvania, USA, November 18, 2026 INOVIO has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency...
PLYMOUTH MEETING, Pennsylvania, U.S., October 30, 2026 INOVIO Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration...
